
CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.
ZNF263 (zinc finger protein 263) encodes a zinc finger transcription factor with DNA-binding and transcriptional regulatory activities. The protein binds cis-regulatory regions associated with RNA polymerase II and can function as a transcriptional repressor or activator. ZNF263 is localized primarily to the nucleus, where it may contribute to regulation of gene expression through sequence-specific interactions with regulatory DNA elements.
The K-562 cell line was established by Lozzio and Lozzio in 1970 from the pleural effusion of a 53-year-old female patient with chronic myeloid leukemia (CML) in blast crisis. The cells carry the BCR-ABL1 e14-a2 (b3-a2) fusion gene and exhibit characteristics of myeloid leukemia cells, including hemoglobin production. K-562 is a human leukemia cell model widely used for studying CML biology, myeloid differentiation, hematopoietic signaling, and immune cell interactions, including applications as an in vitro target model in natural killer (NK) cell assays.
Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 1
Reference Transcript: NM_001411015
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?